1.An Update on the Management of Diabetic Neuropathic Pain: A Few Comments.
The Korean Journal of Pain 2015;28(2):158-159
No abstract available.
Neuralgia*
2.Characteristics of neuropathic pain in Indonesia: A hospital based national clinical survey
Thomas Eko Purwata ; Henny A Sadeli ; Yudiyanta ; Yuneldi Anwar ; Darwin Amir ; Chris Asnawi ; Suroto ; Dani Rahmawati ; Leksmono Partoatmodjo ; Susi Aulina ; Putu Eka Widyadarma ; Moch Dalhar ; Endang Mutiawati ; Theresia Runtuwene ; Lucas Meliala ; Andradi Suryamihardja ; Agus Permadi ; Fredy Sitorus ; Untung Gunarto ; Yusak Mangara Tua Siahaan ; Edison Marpaung ; Yulius Mandua
Neurology Asia 2015;20(4):389-394
We conducted a hospital based study to collect data on the clinical characteristics of neuropathic
pain (NP) patients in neurology outpatients in 13 big cities in Indonesia. We aimed to identify the
clinical characteristics of NP among patients with the symptoms of pain. A simple questionnaire was
conducted to explore the clinical symptoms and signs. Participants who reported of NP symptom was
1,779 (21.8%) among 8,160 patients. The higher prevalence of NP was reported in 41-60 years old
(n= 1,030; 57.9%). It was more prevalent in male (n=1,104; 62.1%). The group of patients with low
educational level has higher prevalence of pain with NP (n=1,177; 66.1%). There are five main clinical
symptoms of NP patients, pinprick sensation (n=589; 33.1%), electric shock like sensation (n=542,
30.5%), burning (n=407, 22.9%), paresthesia (n=401; 22.5%) and hyperalgesia (n=351, 19.7%). In
this study, NP was mostly associated with low back pain (n=509, 28,6%), carpal tunnel syndrome
(n=343; 19.3%), frozen shoulder syndrome (n=191, 10.7%), diabetic neuropathy (n=170, 9.6%) and
brachialgia (n=108, 6.1%). The most frequent modality to treat NP symptoms were adjuvant analgesics,
antidepressants or anticonvulsants (n=1,199; 67.4%), non-steroidal anti-inflammatory drugs (n=1,177,
66.2%), non-opioids analgesics (n=606; 34.1%), non-pharmacological treatment (n=366; 20.6%) and
opioid treatments (n=100, 5.6%).
Neuralgia
3.Medications in Treatment of Postherpetic Neuralgia.
The Korean Journal of Pain 2014;27(1):1-2
No abstract available.
Neuralgia, Postherpetic*
4.Autophagy: Can It be a New Experimental Research Method of Neuropathic Pain?.
The Korean Journal of Pain 2015;28(4):229-230
No abstract available.
Autophagy*
;
Neuralgia*
5.Postherpetic Neuralgia.
Journal of the Korean Medical Association 2001;44(3):315-324
No abstract available.
Neuralgia, Postherpetic*
6.Cervical Myelitis Mimicking Intractable Occipital Neuralgia.
Ji Sun KIM ; Sung Woog LEE ; Byung Jo KIM
Journal of Clinical Neurology 2014;10(1):72-73
No abstract available.
Myelitis*
;
Neuralgia*
7.The Potential Role of Intrathecal Nefopam in the Management of Neuropathic Pain.
Mohamed Amin GHOBADIFAR ; Navid KALANI
The Korean Journal of Pain 2014;27(3):301-302
No abstract available.
Nefopam*
;
Neuralgia*
8.Neurovascular Compression Confirmed by 3D T2-Weighted Volume Isotropic Turbo Spin-Echo Acquisition Sequence in Trigeminal Neuralgia
Seung Ho JEON ; Hong Jin KIM ; Mi Kyoung KANG ; Seung Bae HWANG ; Hyun Goo KANG ; Byoung Soo SHIN
Journal of the Korean Neurological Association 2019;37(3):295-297
No abstract available.
Trigeminal Neuralgia
9.Know Thy Enemy: Untangling the Mysteries of Neuropathic Pain.
Mahar FATIMA ; Chia Chun HOR ; Bo DUAN
Neuroscience Bulletin 2021;37(11):1639-1641
10.Efficacy of Piroxicam Patch Compared to Lidocaine Patch for the Treatment of Postherpetic Neuralgia.
Jun Young KIM ; Hyun Jung LIM ; Weon Ju LEE ; Seok Jong LEE ; Do Won KIM ; Byung Soo KIM
Annals of Dermatology 2011;23(2):162-169
BACKGROUND: The lidocaine patch has been effectively used as a first-line therapy to treat neuropathic pain such as postherpetic neuralgia (PHN). OBJECTIVE: To evaluate the safety and efficacy of the topical piroxicam patch as a treatment option for the treatment of PHN. METHODS: Eighteen patients completed a 3-session study, applying three different patches (lidocaine, piroxicam and control) in random order. A maximum of three patches were applied to the most painful area for three consecutive days (12 hours on followed by 12 hours off). Each session was conducted at least seven days apart. The changes in visual analog scale (VAS) scores based pain intensity, quality of sleep and adverse effects were recorded. RESULTS: When compared to the control, both the lidocaine and piroxicam patches significantly reduced the mean VAS scores of pain intensity of all different types. However, the lidocaine patch was better at reducing allodynia, whereas the piroxicam patch was more effective for dull pain. The lidocaine patch worked faster than the piroxicam patch for the response to overall pain relief. CONCLUSION: The results of this study suggest the use of the piroxicam patch for dull pain and in patients where the lidocaine patch is contraindicated.
Humans
;
Hyperalgesia
;
Lidocaine
;
Neuralgia
;
Neuralgia, Postherpetic
;
Piroxicam